Luteolin inhibits inflammatory responses by downregulating the JNK, NF-κB, and AP-1 pathways in TNF-α activated HepG2 cells

Food Science and Biotechnology

Volumn 21, Issue 1, 2012, Pages 279-283

  Park, Chung Mu ^a   Jin, Kyong Suk ^b   Cho, Chung Won ^a   Lee, Yong Woo ^a   Huh, Gyung Hye ^a   Cha, Youn Soo ^c   Song, Young Sun ^a  

^a Inje University   (South Korea)

^b Dong Eui University   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

activator protein 1 (AP 1); c Jun N terminal kinase (JNK); inducible nitric oxide synthase (iNOS); luteolin; nuclear factor (NF) B

Indexed keywords

ACTIVATOR PROTEIN-1; C-JUN N-TERMINAL KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE (INOS); LUTEOLIN; NUCLEAR FACTORS;

CHEMICAL ACTIVATION; NITRIC OXIDE; PATHOLOGY; TRANSCRIPTION FACTORS;

PHOSPHORYLATION;

EID: 84862893295     PISSN: 12267708     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10068-012-0037-x     Document Type: Article

References (23)

1. Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L, Geller DA. Wnt/β-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-κB activation in cancer cells. Cancer Res. 69: 3764-3671 (2009).
2. Yu Z, Zhang W, Kone BC. Histone deacetylases augment cytokine induction of the iNOS gene. J. Am. Soc. Nephrol. 13: 2009-2017 (2002).
3. Majano PL, Medina J, Zubia I, Sunyer L, Lara-Pezzi E, Maldonado-Rodriguez A, Lopez-Cabrera M, Moreno-Otero R. N-Acetylcysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J. Hepatol. 40: 632-637 (2004).
4. Kundu JK, Surh YJ. Inflammation: Gearing the journey to cancer. Mutat. Res. 659: 15-30 (2008).
5. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radical Bio. Med. 28: 463-499 (2000).
6. Gius D, Botero A, Shah S, Curry HA. Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1. Toxicol. Lett. 106: 93-106 (1999).
7. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. P. Natl. Acad. Sci. USA 105: 7534-7539 (2008).
8. Harris GK, Qian Y, Leonard SS, Sbarra DC, Shi X. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264. 7 cells. J. Nutr. 136: 1517-1521 (2006).
9. Knasmuller S, Parzefall W, Sanyal R, Ecker S, Schwab C, Uhl M, Mersch-Sundermann V, Williamson G, Hietsch G, Langer T, Darroudi F, Natarajan AT. Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat. Res. 402: 185-202 (1998).
10. Knasmuller S, Mersch-Sundermann V, Kevekordes S, Darroudi F, Huber WW, Hoelzl C, Bichler J, Majer BJ. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198: 315-328 (2004).
11. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic, and cogenotoxic agents. Toxicology 198: 329-340 (2004).
12. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, antiinflammatory, and anti-allergic activities of luteolin. Planta Med. 74: 1667-1677 (2008).
13. Chen CY, Peng WH, Wu LC, Wu CC, Hsu SL. Luteolin ameliorates experimental lung fibrosis both in vivo and in vitro: Implications for therapy of lung fibrosis. J. Agr. Food Chem. 58: 11653-11661 (2010).
14. Dai Z, Nair V, Khan M, Ciolino HP. Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in vitro. Oncol. Rep. 24: 1087-1091 (2010).
15. Lee JP, Li YC, Chen HY, Lin RH, Huang SS, Chen HL, Kuan PC, Liao MF, Chen CJ, Kuan YH. Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils. Acta Pharmacol. Sin. 31: 831-838 (2010).
16. Verschooten L, Smaers K, van Kelst S, Proby C, Maes D, Declercq L, Agostinis P, Garmyn M. The flavonoid luteolin increases the resistance of normal, but not malignant keratinocytes, against UVBinduced apoptosis. J. Invest. Dermatol. 130: 2277-2285 (2010).
17. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben AM, Bracke M, Awad S, John A, Kamalboor HA, Al Sultan MA, Arafat K, Gespach C, Petroianu G. Inhibition of cell survival, invasion, tumor growth, and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur. J. Pharmacol. 651: 18-25 (2011).
18. Liu J-F, Ma Y, Wang Y, Du Z-Y, Shen J-K, Peng H-L. Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother. Res. 25: 588-596 (2010).
19. Li J, Billiar TR. Nitric oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am. J. Physiol. 276: G1069-G1073 (1999).
20. Crowell JA, Steele VE, Sigman CC, Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther. 2: 815-823 (2003).
21. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ. NF-κB and AP-1 connection: Mechanism of NF-κB-dependent regulation of AP-1 activity. Mol. Cell Biol. 24: 7806-7819 (2004).
22. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3: 768-780 (2003).
23. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912 (2002).